newest glp 1 drug Retatrutide for weight loss: Study shows 30% body weight loss New research is challenging long-held

Stopping GLP-1R agonists preoperatively may lead to worsened glycaemia and metabolic instability

The impact of GLP-1 RAs on lipid synthesis and oxidation in the liver, resulting in decreased inflammation and fibrosis, has led to studies evaluating their potential for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH), and inflammatory bowel disease (IBD), and the prevention of hepatobiliary and other gastrointestinal (GI) cancers [1,5]

Key takeaways IIH causes elevated brain pressure without a tumor or other structural cause Most common in young, overweight women of childbearing age Symptoms : headaches, transient vision changes, pulsatile tinnitus, double vision Papilledema (optic disc swelling) is the key finding Treatment focuses on weight loss, medications, and protecting vision Vision can be permanently damaged if not monitored and treated Questions about your diagnosis

Heres how to approach holistically: GLP-1 Receptor Agonists: They encourage insulin release, improving blood glucose levels

Clinical eligibility for GLP-1 drugs was determined using BMI and the following comorbidities as specified in NHIS: coronary heart disease, prior stroke, prior heart attack, angina, high blood pressure, and high cholesterol

People should be aware of potential eye disease and blindness risks when discussing a GLP-1 with their doctor